‘Extremely impressive’: melanoma jab trial results excite doctors The GuardianModerna, Merck say vaccine improved survival in patients with deadly skin cancer CNBCExperimental mRNA vaccines gain steam with promising cancer trial results SemaforMelanoma vaccine lowers death, reoccurrence risk by 49 per cent, trial finds 9NewsModerna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in P Yahoo Finance